$272 Million is the total value of Parkman Healthcare Partners LLC's 76 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 40.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Sell | SEAGEN INC | $13,558,000 | +9.3% | 76,626 | -11.0% | 4.99% | +37.5% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $8,960,000 | -3.6% | 294,559 | -3.2% | 3.30% | +21.3% |
| IQV | Sell | IQVIA HLDGS INC | $8,615,000 | -25.6% | 39,701 | -20.7% | 3.17% | -6.4% |
| IRTC | Sell | IRHYTHM TECHNOLOGIES INC | $7,994,000 | -51.2% | 74,001 | -28.8% | 2.94% | -38.6% |
| CTLT | Sell | CATALENT INC | $7,255,000 | -17.2% | 67,618 | -14.5% | 2.67% | +4.1% |
| LEGN | Sell | LEGEND BIOTECH CORPsponsored ads | $6,479,000 | +48.0% | 117,807 | -2.2% | 2.39% | +86.3% |
| CVS | Sell | CVS HEALTH CORP | $4,962,000 | -42.7% | 53,547 | -37.5% | 1.83% | -28.0% |
| THC | Sell | TENET HEALTHCARE CORP | $4,846,000 | -59.5% | 92,190 | -33.8% | 1.78% | -49.0% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $4,256,000 | -63.0% | 304,843 | -54.4% | 1.57% | -53.5% |
| COO | Sell | COOPER COS INC | $3,288,000 | -59.8% | 10,500 | -46.4% | 1.21% | -49.4% |
| MASS | Sell | 908 DEVICES INC | $3,074,000 | -7.6% | 149,315 | -14.7% | 1.13% | +16.2% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $3,024,000 | -65.7% | 20,734 | -61.6% | 1.11% | -56.8% |
| NTRA | Sell | NATERA INC | $2,624,000 | -50.4% | 74,047 | -43.0% | 0.97% | -37.6% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $2,564,000 | -27.2% | 88,658 | -18.6% | 0.94% | -8.3% |
| APEN | Sell | APOLLO ENDOSURGERY INC | $2,373,000 | -51.6% | 650,000 | -19.8% | 0.87% | -39.1% |
| IMUX | Sell | IMMUNIC INC | $2,256,000 | -81.7% | 650,028 | -40.3% | 0.83% | -76.9% |
| CDXS | Sell | CODEXIS INC | $2,134,000 | -61.4% | 204,049 | -23.9% | 0.79% | -51.4% |
| LNTH | Sell | LANTHEUS HLDGS INC | $1,415,000 | +1.1% | 21,427 | -15.3% | 0.52% | +27.4% |
| KROS | Sell | KEROS THERAPEUTICS INC | $1,320,000 | -66.6% | 47,788 | -34.3% | 0.49% | -58.0% |
| HBIO | Sell | HARVARD BIOSCIENCE INC | $1,266,000 | -67.8% | 351,750 | -44.5% | 0.47% | -59.5% |
| STRO | Sell | SUTRO BIOPHARMA INC | $961,000 | -41.5% | 184,518 | -7.7% | 0.35% | -26.4% |
| HCAT | Sell | HEALTH CATALYST INC | $914,000 | -56.1% | 63,104 | -20.9% | 0.34% | -44.8% |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $542,000 | -53.1% | 78,603 | -36.8% | 0.20% | -40.8% |
| SIEN | Sell | SIENTRA INC | $351,000 | -70.3% | 419,176 | -21.2% | 0.13% | -62.7% |
| SURF | Sell | SURFACE ONCOLOGY INC | $190,000 | -69.1% | 115,577 | -44.7% | 0.07% | -61.1% |
| VSTM | Exit | VERASTEM INC | $0 | – | -190,755 | -100.0% | -0.08% | – |
| NRIX | Exit | NURIX THERAPEUTICS INC | $0 | – | -20,663 | -100.0% | -0.08% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -103,709 | -100.0% | -0.10% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -37,285 | -100.0% | -0.27% | – |
| REPH | Exit | SOCIETAL CDMO INC | $0 | – | -671,817 | -100.0% | -0.35% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -15,236 | -100.0% | -0.37% | – |
| ATRC | Exit | ATRICURE INC | $0 | – | -25,236 | -100.0% | -0.48% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -200,185 | -100.0% | -0.51% | – |
| MRVI | Exit | MARAVAI LIFESCIENCES HLDGS I | $0 | – | -77,389 | -100.0% | -0.80% | – |
| CRL | Exit | CHARLES RIV LABS INTL INC | $0 | – | -10,000 | -100.0% | -0.83% | – |
| OM | Exit | OUTSET MED INC | $0 | – | -81,601 | -100.0% | -1.08% | – |
| TFX | Exit | TELEFLEX INCORPORATED | $0 | – | -12,500 | -100.0% | -1.30% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -151,915 | -100.0% | -1.42% | – |
| IDXX | Exit | IDEXX LABS INC | $0 | – | -9,388 | -100.0% | -1.50% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -45,731 | -100.0% | -2.17% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -476,978 | -100.0% | -2.27% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -342,923 | -100.0% | -2.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 16 | Q3 2023 | 6.3% |
| ACLARIS THERAPEUTICS INC | 16 | Q3 2023 | 10.0% |
| XENON PHARMACEUTICALS INC | 16 | Q3 2023 | 3.3% |
| NATERA INC | 16 | Q3 2023 | 3.4% |
| AVID BIOSERVICES INC | 15 | Q3 2023 | 2.9% |
| SCHRODINGER INC | 15 | Q3 2023 | 4.2% |
| REPRO MED SYS INC | 15 | Q2 2023 | 2.0% |
| MANNKIND CORP | 15 | Q3 2023 | 1.6% |
| IQVIA HLDGS INC | 14 | Q1 2023 | 4.6% |
| INSULET CORP | 14 | Q3 2023 | 2.9% |
View Parkman Healthcare Partners LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PLUS THERAPEUTICS, INC. | February 13, 2023 | 583,467 | 1.7% |
View Parkman Healthcare Partners LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Parkman Healthcare Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.